Positive results from further Eroxon® Intense HUT

Futura’s new Eroxon Intense formula shows clear clinical gains but commercial launch is months away.

What the company is saying

Futura Medical plc is announcing statistically significant improvements from a Home User Test of its optimised Eroxon Intense formula, which is targeted for commercial launch in the first half of 2027. The company frames the results as a major step forward, highlighting that 82% of sexual encounters resulted in satisfaction with erection hardness (up from 71% and 70% in prior formulations), and 87% of encounters lasted long enough for intercourse (up from 85% and 84%). The IIEF-EF scale showed a 7.86-point improvement from baseline, compared to 4.82 previously, with 87% of men with moderate ED achieving clinically meaningful improvement versus 73% before. Futura emphasises that these results exceed clinically meaningful thresholds and reinforce the product’s differentiation, especially for moderate ED. The announcement is confident in tone, with Ken James (Executive Director and Head of R&D) stating the new formula enhances user experience and supports the company's belief in the value of clear product communication. The company also states that work is nearly complete on market positioning, and reiterates its intention to launch commercially in H1 2027.

What the data suggests

The disclosed figures show the optimised Eroxon Intense formula outperforms both the original Intense and current Eroxon in all measured clinical endpoints. Satisfaction with erection hardness improved to 82% (from 71% and 70%), and erections lasting long enough for intercourse rose to 87% (from 85% and 84%). The IIEF-EF scale improvement of 7.86 points is substantially above the 4.82-point gain previously seen and exceeds the threshold for clinical significance. Among men with moderate ED, the proportion achieving clinically meaningful improvement increased to 87% from 73%. The study involved 115 men aged 18-59, mostly with mild to moderate ED. No financial, regulatory, or commercialisation metrics are disclosed for the new formula, and there is no quantified data on user satisfaction or purchase intent beyond the clinical endpoints. The evidence for improved efficacy is robust, but the announcement does not provide information on manufacturing, regulatory progress, or commercial agreements for the new formulation.

Analysis

The announcement is upbeat and highlights statistically significant improvements in clinical outcomes for the new Eroxon® Intense formula, supported by comparative numerical data from the Home User Test. However, the majority of the forward-looking claims relate to commercialisation and market positioning, which are not imminent (planned for H1 2027, nearly two years away). No financial, revenue, or profitability metrics are disclosed, and there is no information on regulatory status, manufacturing readiness, or commercial agreements for the new formulation. While the clinical data is robust, the narrative inflates the signal by implying near-term commercial impact and broad market readiness, which are not yet realised. The absence of capital outlay or immediate earnings impact means capital intensity is not a concern, but the long execution distance and lack of commercial detail limit the strength of the signal.

Risk flags

• ●The timeline to commercial launch is at least six months away, introducing execution risk around regulatory approval, manufacturing readiness, and final market positioning. Delays or setbacks in any of these areas could push back revenue generation.
• ●No financial, regulatory, or commercial details are disclosed for the new Intense formulation, making it impossible to assess the revenue potential, cost structure, or likelihood of successful market entry. This lack of commercial visibility is a material risk for investors.
• ●The announcement does not specify whether the improved clinical results will translate into greater market adoption or commercial success, especially given the competitive landscape and the need for effective product communication and positioning.

Bottom line

Futura Medical’s new Eroxon Intense formula delivers clear, statistically significant clinical improvements over previous iterations, with satisfaction and efficacy rates rising across all key measures. The company is confident about the product’s differentiation and is progressing toward a commercial launch in H1 2027, but no regulatory, manufacturing, or financial milestones have been disclosed for the new formula. The absence of commercial details and the six-month-plus timeline mean investors will need to wait for further updates on regulatory approval, production readiness, and distribution agreements. The most important takeaway is that while clinical efficacy is now well-demonstrated, the path to commercial value still depends on successful execution of regulatory and go-to-market steps. Investors should watch for concrete commercial and regulatory milestones in the coming quarters.

Announcement summary

(AIM:FUM) Futura Medical plc announced positive results from an additional Home User Test (HUT) of its new Eroxon® “Intense” formula, which is intended for commercialisation in H1 2027. The HUT evaluated the optimised Intense presentation in 115 men aged 18-59, most of whom had mild to moderate erectile dysfunction. The study design was broadly identical to the previous HUT announced on 23 March 2026, allowing direct comparison. The optimised Intense presentation improved performance across all key measures compared with both the original Intense presentation and the current Eroxon® formulation. Participants reported satisfaction with erection hardness in 82% of sexual encounters, compared with 71% for the original Intense and 70% for Eroxon® in the previous study. Erections lasted long enough for intercourse in 87% of encounters, compared with 85% and 84% respectively. On the IIEF-EF scale, participants achieved a 7.86-point improvement from baseline, compared with 4.82 points in the previous study of original Intense. Among men with moderate ED, 87% achieved a clinically meaningful improvement versus 73% previously. Ratings, user satisfaction, and purchase intent all improved compared with the previous study on the original Eroxon Intense presentation. The optimised Intense presentation delivered meaningful improvements across all key performance measures. Work is nearing completion to finalise the product's market positioning ahead of the planned H1 2027 launch. The results further support the company's belief that clear communication around product use will deliver increased customer satisfaction. Ken James, Executive Director and Head of R&D, stated that the optimised Intense product delivered improvements across all key measures compared with previous study results, reinforcing the potential to further enhance the user experience. The company remains on track to complete brand positioning work and prepare for the planned commercial launch in the first half of 2027. Futura Medical plc's lead product is Eroxon®, a clinically proven topical gel treatment for erectile dysfunction, and the company is also developing WSD4000, a female sexual health portfolio. Multiple license or distribution partnerships are in place for Eroxon® across major consumer markets.

Disagree with this article?